Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ovid Therapeutics Inc (NQ: OVID )

3.060 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 78,572
Open 3.090
Bid (Size) 3.060 (46)
Ask (Size) 3.070 (9)
Prev. Close 3.060
Today's Range 3.021 - 3.123
52wk Range 2.570 - 4.139
Shares Outstanding 70,417,345
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 Sorry Penny Stocks to Sell in May While You Still Can
Steer clear of these three penny stocks to sell that are plagued by financial instability and mounting losses. 
Via InvestorPlace
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for May 2024
Although the concept of penny stocks to buy is extremely risky, these ideas have the advantage of analysts’ positive assessments. 
Via InvestorPlace

Performance

YTD
-7.83%
-7.83%
1 Month
-2.86%
-2.86%
3 Month
-17.30%
-17.30%
6 Month
-8.11%
-8.11%
1 Year
-14.53%
-14.53%

More News

Read More
OVID Stock Earnings: Ovid Therapeutics Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
Cracking The Code: Understanding Analyst Reviews For Ovid Therapeutics
Via Benzinga
Recap: Ovid Therapeutics Q4 Earnings
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
Over $2M Bet On NextNav? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
Via Benzinga
Topics Stocks
Exposures US Equities
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics to Participate in Upcoming September Investor Conferences
From Ovid Therapeutics Inc.
Via GlobeNewswire
3 Very Promising Penny Stocks That Are Flying Under the Radar
Via InvestorPlace
Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer
From Ovid Therapeutics Inc.
Via GlobeNewswire
Ovid Therapeutics Added to Russell 3000® Index
From Ovid Therapeutics Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.